Lipolytic Effects of GH in Human Subjects in Vivo
NCT02782221 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9
Last updated 2020-03-26
Summary
Growth hormone (GH) induces fat metabolism. The mechanisms underlying the fat metabolizing effects of GH remain elusive. However, it is known that insulin suppresses fat metabolism, and GH inhibits the expression of certain insulin-dependent signaling proteins. We therefore hypothesize that the fat metabolizing effects of GH depend on abrogation of insulin-dependent signaling pathways.
In order to investigate the fat metabolizing effects of GH, we'll analyze consecutive adipose tissue biopsies taken after GH exposure and GH blocking, respectively.
Knowledge of the effects of growth hormone and fat metabolism can in shot-sight as well as in long-sight have great importance for the understanding of growth disorders from overweight and type 2 diabetes to malnutrition and eating disorders.
Conditions
- Metabolic Diseases
- Growth Hormone Treatment
Interventions
- DRUG
-
Growth Hormone
Subjects are receiving one injection of growth hormone (Genotropin) 0,5 mg
- DRUG
-
Pegisomant
One the placebo day the subjects are receiving injection with pegvisomant (Somavert 30 mg) to block the action of endogenous growth hormone
Sponsors & Collaborators
-
University of Aarhus
lead OTHER
Principal Investigators
-
Jens Otto L Jørgensen, Professor · University Hospital of Aarhus
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- SINGLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2016-05-30
- Primary Completion
- 2016-09-22
- Completion
- 2017-01-15
Countries
- Denmark
Study Locations
More Related Trials
-
Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content
NCT00476879 ·Status: COMPLETED ·Phase: NA
-
Effect of a Test Meal on Satiation Hormones in Obese and Normal Weight Adolescents
NCT02020395 ·Status: COMPLETED ·Phase: PHASE1
-
Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency
NCT01804413 ·Status: UNKNOWN ·Phase: NA
-
Growth Hormone as a Model for Reversible Activation of Adipose Tissue Fibrosis
NCT04998500 ·Status: UNKNOWN ·Phase: NA
-
The Effect of Growth Hormone Replacement on Liver Fat
NCT00774579 ·Status: COMPLETED
-
Effects of GH and Lirglutide on AgRP
NCT05681299 ·Status: RECRUITING ·Phase: PHASE4
-
Growth Hormone as a Determinant of Weight Regulation
NCT00355784 ·Status: COMPLETED ·Phase: NA
-
Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates
NCT00517062 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Growth Hormone Treatment on Phosphocreatine Recovery in Obesity
NCT01421589 ·Status: COMPLETED ·Phase: NA
-
Low Dose Growth Hormone Treatment in Subjects With Metabolic Syndrome.
NCT00720616 ·Status: WITHDRAWN ·Phase: NA
-
Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children
NCT01237041 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin
NCT01209416 ·Status: COMPLETED ·Phase: NA
-
Growth Hormone Treatment in Men With High Risk of Developing Type 2 Diabetes Mellitus
NCT00781547 ·Status: COMPLETED ·Phase: PHASE3
-
The Relationship Between the Growth Hormone (GH)- Insulin Like Growth Factor I (IGF-I) System and the Inflammatory System in Healthy Normal Persons
NCT00969644 ·Status: UNKNOWN ·Phase: NA
-
Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers
NCT02418767 ·Status: COMPLETED ·Phase: PHASE1
-
Ghrelin, Growth Hormone and Cortisol Interaction in Growth Hormone Deficient Patients
NCT00139945 ·Status: COMPLETED ·Phase: NA
-
Treatment of Adults With Growth Hormone Deficiency
NCT00294619 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Growth Hormone and IGF-1 on Anabolic Signals and Stem Cell Recruitment in Human Skeletal Muscle
NCT03878992 ·Status: UNKNOWN ·Phase: NA
-
Effect of Pegvisomant on GH/IGF-I Relationship in GHD
NCT00468624 ·Status: TERMINATED ·Phase: NA
-
Growth Hormone, Cardiovascular Risk, and Visceral Adiposity
NCT00131378 ·Status: COMPLETED ·Phase: NA
-
Study of the Molecular Basis in the Pathophysiology of Food Intake and Growth in Children
NCT00830141 ·Status: COMPLETED
-
Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls
NCT01169103 ·Status: COMPLETED ·Phase: PHASE2
-
Acute Application of Pegvisomant and Octreotide in Acromegaly
NCT00595140 ·Status: COMPLETED ·Phase: PHASE4
-
The Effects of Growth Hormone (GH) on Lipid Depots
NCT00491582 ·Status: COMPLETED ·Phase: NA
-
Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children
NCT02314676 ·Status: UNKNOWN ·Phase: PHASE4